<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704065</url>
  </required_header>
  <id_info>
    <org_study_id>32447/199</org_study_id>
    <nct_id>NCT02704065</nct_id>
  </id_info>
  <brief_title>Recurrent AA Amyloidosis After Renal Transplantation</brief_title>
  <official_title>Recurrent AA Amyloidosis After Renal Transplantation: Effects on Allograft Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End-stage renal disease related to AA amyloidosis is well characterized but there is limited
      data concerning patient and graft outcomes after renal transplantation. The aim of this study
      is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as
      well as the effects of these factors on the ultimate outcome of renal allografts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases
      including recurrent hereditary periodic fever syndromes. Although end-stage renal disease
      related to AA amyloidosis is well characterized, there is limited data concerning patient and
      graft outcomes after renal transplantation, with most of the findings reported from small
      series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing
      graft and patient outcomes in larger study groups will bring better understanding and new
      strategies in daily practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Allograft survival</measure>
    <time_frame>1 - 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allograft rejection</measure>
    <time_frame>1 - 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">54</enrollment>
  <condition>AA Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Recurrent AA amyloidosis</arm_group_label>
    <description>Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 1</arm_group_label>
    <description>Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2</arm_group_label>
    <description>Renal transplant recipients whose primary diseases are other than amyloidosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Renal transplant recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplantation recipients whose primary renal disease is AA amyloidosis;
             patients with allograft biopsy-confirmed AA amyloidosis (for study group) and patients
             with no clinical or laboratory signs of recurrence in the renal allograft (for control
             group 1)

          -  Renal transplantation recipients whose primary diseases are other than AA amyloidosis
             (for control group 2)

        Exclusion Criteria:

          -  Patients who are unwilling or unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasar Caliskan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Sisli Hamidiye Etfal Training and Education Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Kofman T, Grimbert P, Canou√Ø-Poitrine F, Zuber J, Garrigue V, Mousson C, Frimat L, Kamar N, Couvrat G, Bouvier N, Albano L, Le Thuaut A, Pillebout E, Choukroun G, Couzi L, Peltier J, Mariat C, Delahousse M, Buchler M, Le Pogamp P, Bridoux F, Pouteil-Noble C, Lang P, Audard V. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant. 2011 Nov;11(11):2423-31. doi: 10.1111/j.1600-6143.2011.03620.x. Epub 2011 Jun 30.</citation>
    <PMID>21714848</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>April 15, 2017</last_update_submitted>
  <last_update_submitted_qc>April 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Yasar Caliskan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>amyloidosis</keyword>
  <keyword>renal transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

